maintenance dosing semaglutide with Tirzepatide and Semaglutide: What the data tells us is there a maintenance dose

Specifically, tirzepatide is a dual GIP/GLP-1 receptor agonist

Preclinical (animal) data Rodent studies suggest BPC-157 may: Promote blood vessel growth Enhance tendon fibroblast activity Reduce inflammation Protect gastrointestinal tissues However, these findings: Use doses far above any human equivalent Use controlled laboratory injuries Do not predict human efficacy 2

Apply them at 7 AM, and peak penetration occurs during the day when your skin is in protection mode rather than repair mode

Track progress through multiple metrics: scale weight (understanding water fluctuations affect this), body measurements at consistent points, progress photos in consistent lighting and posture, and subjective assessments of how clothing fits